Kadayat Tara Man, Banskota Suhrid, Bist Ganesh, Gurung Pallavi, Magar Til Bahadur Thapa, Shrestha Aarajana, Kim Jung-Ae, Lee Eung-Seok
College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea; New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Bioorg Med Chem Lett. 2018 Aug 1;28(14):2436-2441. doi: 10.1016/j.bmcl.2018.06.012. Epub 2018 Jun 8.
A series of pyridine-linked indanone derivatives were designed and synthesized to discover new small molecules for the treatment of inflammatory bowel disease (IBD). Compounds 5b and 5d exhibited strongest inhibitory activity against TNF-α-induced monocyte adhesion to colon epithelial cells (an in vitro model of colitis). In TNBS (2,4,6-trinitrobenzenesulfonic acid)-induced rat colitis model, oral administration of the compounds 5b and 5d ameliorated colitis with significant recovery in altered expressions of E-cadherin, TNF-α and IL-1β expressions, indicating 5b and 5d as potential agents for therapeutics development against IBD.
设计并合成了一系列吡啶连接的茚满二酮衍生物,以发现用于治疗炎症性肠病(IBD)的新型小分子。化合物5b和5d对肿瘤坏死因子-α(TNF-α)诱导的单核细胞与结肠上皮细胞黏附(一种结肠炎体外模型)表现出最强的抑制活性。在2,4,6-三硝基苯磺酸(TNBS)诱导的大鼠结肠炎模型中,口服化合物5b和5d可改善结肠炎,E-钙黏蛋白、TNF-α和白细胞介素-1β表达的改变得到显著恢复,表明5b和5d是开发抗IBD治疗药物的潜在药物。